T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

RegulatoryMT027Positive

AI Analysis

Summary

T-MAXIMUM announced that the FDA has cleared it to begin a Phase 2 clinical study of MT027, its B7-H3-targeted allogeneic CAR-T, in brain metastases from lung and breast cancer. The company is Beijing-based and the article provides no further trial details.

Clinical Trial Data

Phase

Phase 2

Outcome Details

FDA cleared the company to initiate a Phase 2 clinical study of MT027, a B7-H3-targeted allogeneic CAR-T.

Importance:5/10

Sentiment:

0.50

CAR-TallogeneicB7-H3brain metastaseslung cancerbreast cancerIND clearanceFDAoncologycell therapy

Related Companies

$UHS $BNN.DE

Read the original article

Published by PR Newswire Pharma on October 12, 2026 10:50 AM

Read Original